The proportion of patients with progression at 24 months or complete response at 30 months are considered potential surrogate endpoints for overall survival (OS) in first line follicular lymphoma. I explore OS predictions conditional on a patient’s status at 24 or 30 months based on a multistate model applied to data of a pivotal Phase 3 trial and discuss some connections of multistate models over alternatives.